Entering text into the input field will update the search result below

Combination of AbbVie's venetoclax and Rituxan successful in late-stage leukemia study

Dec. 12, 2017 10:32 AM ETAbbVie Inc. (ABBV) StockBy: Douglas W. House, SA News Editor2 Comments
  • A Phase 3 clinical trial, MURANO, assessing AbbVie's (NYSE:ABBV -1.1%) VENCLEXTA/VENCYXTO (venetoclax) combined with Roche unit (OTCQX:RHHBY) Genentech's Rituxan (rituximab) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) showed a treatment benefit compared to bendamustine + Rituxan. The results were presented at ASH in Atlanta.
  • Treatment with venetoclax/rituximab significantly extended progression-free survival (PFS) compared to bendamustine/rituximab. Specifically, median PFS for the venetoclax combo was not reached compared to 17.0 months for the bendamustine combo. 24-month PFS estimates were 84.9% and 36.5%, respectively.
  • Regulatory submissions seeking approval for the combination are underway.
  • AbbVie and Roche are co-developing venetoclax. AbbVie and Genentech are co-commercializing in the U.S. while AbbVie is commercializing ex-U.S.
  • Venetoclax is a small molecule inhibitor of a protein called B-cell lymphoma-2 (BCL-2) which plays a key role in apoptosis (programmed cell death). Blocking BCL-2 is believed to restore the signaling system that tells cancer cells to self-destruct.

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABBV--
AbbVie Inc.